J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
India · Delayed Price · Currency is INR 2,416.10
+7.20 (0.30%)
Jul 16, 2026, 3:29 PM IST
NSE:JBCHEPHARM Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 41,478 | 39,180 | 34,842 | 31,493 | 24,242 | |
Revenue Growth | 5.87% | 12.45% | 10.63% | 29.91% | 18.69% |
Cost of Revenue | 13,369 | 13,545 | 12,142 | 11,963 | 8,655 |
Gross Profit | 28,109 | 25,635 | 22,700 | 19,530 | 15,588 |
Selling, General & Admin | 10,427 | 9,172 | 8,111 | 7,278 | 5,662 |
Other Operating Expenses | 6,628 | 6,153 | 5,661 | 5,190 | 4,460 |
Operating Expenses | 18,881 | 17,035 | 15,156 | 13,612 | 10,849 |
Operating Income | 9,228 | 8,600 | 7,544 | 5,918 | 4,739 |
Interest Expense | -49.76 | -106.45 | -436.52 | -347.68 | -40.85 |
Interest & Investment Income | 337.48 | 53.31 | 44.26 | 25.39 | 9.39 |
Currency Exchange Gain (Loss) | 16.77 | 7.18 | 44.07 | -110.87 | -38.01 |
Other Non Operating Income (Expenses) | 5.23 | -4.72 | -5.79 | -2.79 | 1.06 |
EBT Excluding Unusual Items | 9,538 | 8,550 | 7,190 | 5,482 | 4,671 |
Gain (Loss) on Sale of Investments | 251.74 | 322.08 | 327.43 | 69 | 350.43 |
Gain (Loss) on Sale of Assets | 5.74 | 2.12 | -2.32 | 0.07 | 24.05 |
Other Unusual Items | -271.78 | - | - | 1.28 | 3.98 |
Pretax Income | 9,523 | 8,874 | 7,515 | 5,552 | 5,049 |
Income Tax Expense | 2,429 | 2,278 | 1,989 | 1,452 | 1,189 |
Earnings From Continuing Operations | 7,095 | 6,596 | 5,526 | 4,100 | 3,860 |
Minority Interest in Earnings | - | - | - | -1.7 | -6.82 |
Net Income | 7,095 | 6,596 | 5,526 | 4,098 | 3,854 |
Net Income to Common | 7,095 | 6,596 | 5,526 | 4,098 | 3,854 |
Net Income Growth | 7.56% | 19.35% | 34.84% | 6.35% | -13.98% |
Shares Outstanding (Basic) | 157 | 155 | 155 | 155 | 155 |
Shares Outstanding (Diluted) | 160 | 159 | 159 | 157 | 155 |
Shares Change | 0.59% | 0.07% | 1.26% | 1.23% | 0.10% |
EPS (Basic) | 45.16 | 42.45 | 35.66 | 26.50 | 24.93 |
EPS (Diluted) | 44.45 | 41.56 | 34.85 | 26.17 | 24.91 |
EPS Growth | 6.95% | 19.25% | 33.17% | 5.06% | -14.04% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 6,207 | 8,049 | 6,737 | 5,562 | 1,073 |
Free Cash Flow Per Share | 38.89 | 50.72 | 42.48 | 35.51 | 6.93 |
Dividend Per Share | 22.000 | 15.500 | 12.250 | 8.875 | 8.250 |
Dividend Growth | 41.94% | 26.53% | 38.03% | 7.58% | 0% |
Gross Margin | 67.77% | 65.43% | 65.15% | 62.01% | 64.30% |
Operating Margin | 22.25% | 21.95% | 21.65% | 18.79% | 19.55% |
Profit Margin | 17.11% | 16.84% | 15.86% | 13.01% | 15.90% |
Free Cash Flow Margin | 14.96% | 20.54% | 19.34% | 17.66% | 4.42% |
EBITDA | 10,907 | 10,188 | 8,813 | 7,038 | 5,384 |
EBITDA Margin | 26.30% | 26.00% | 25.30% | 22.35% | 22.21% |
D&A For EBITDA | 1,679 | 1,588 | 1,269 | 1,120 | 645.45 |
EBIT | 9,228 | 8,600 | 7,544 | 5,918 | 4,739 |
EBIT Margin | 22.25% | 21.95% | 21.65% | 18.79% | 19.55% |
Effective Tax Rate | 25.50% | 25.67% | 26.46% | 26.16% | 23.54% |
Revenue as Reported | 42,079 | 39,563 | 35,214 | 31,592 | 24,635 |
Advertising Expenses | 2,664 | 2,273 | 2,077 | 1,808 | 1,250 |